Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Full details and steps to take here.

NEU Insider Trading

Insider Ownership Percentage: 13.92%
Insider Buying (Last 12 Months): A$59,950.00
Insider Selling (Last 12 Months): A$15,275,000.00

Neuren Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Neuren Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Neuren Pharmaceuticals Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for NEU up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Learn more here.

Neuren Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/13/2023Joseph(Joe) BasileInsiderBuy5,000A$11.99A$59,950.00
6/14/2023Trevor ScottInsiderSell1,175,000A$13.00A$15,275,000.00
10/18/2021Dianne AngusInsiderBuy30,000A$1.98A$59,310.00
10/8/2021Patrick DaviesInsiderBuy14,634A$2.05A$29,999.70
6/24/2021Patrick DaviesInsiderBuy43,694A$1.40A$61,171.60
6/15/2021Jonathan (Jon) PilcherInsiderBuy19,039A$1.31A$24,998.21
See Full Table

SEC Filings (Institutional Ownership Changes) for Neuren Pharmaceuticals (ASX:NEU)

16.27% of Neuren Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Neuren Pharmaceuticals logo
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.
Read More on Neuren Pharmaceuticals

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

57,935 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.98

Who are the company insiders with the largest holdings of Neuren Pharmaceuticals?

Neuren Pharmaceuticals' top insider investors include:
  1. Joseph(Joe) Basile (Insider)
  2. Trevor Scott (Insider)
Learn More about top insider investors at Neuren Pharmaceuticals.